A study of AE37 cancer vaccine in combination with anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab) for the treatment of metastatic triple-negative breast cancer

Trial Profile

A study of AE37 cancer vaccine in combination with anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab) for the treatment of metastatic triple-negative breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs AE 37 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Antigen Express
  • Most Recent Events

    • 04 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top